Financial News
Incannex appoints principal investigators for pivotal IHL-42X trial
By:
TheNewswire.com
June 19, 2023 at 11:20 AM EDT
Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X, a treatment for obstructive sleep apnoea (OSA). The investigators, Dr John D Hudson of FutureSearch Trials of Neurology in Austin, Texas, and Dr Russell Rosenberg of Neurotrials Research Inc in Atlanta, Georgia, will play a crucial role overseeing the first clinical trial sites, handling submissions to the FDA and obtaining ethics approval from Institutional Review Boards.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Jonathan@proactiveinvestors.com
More News
View More
3 Defense Leaders Set to Gain From Rising Military Spend
Today 12:18 EDT
Via MarketBeat
MarketBeat Week in Review – 06/30 - 07/04
Today 7:00 EDT
The Apple Comeback Will Be Better Than the Setback
July 04, 2025
How a Government Loan Changes the Game for Plug Power
July 04, 2025
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.